Antiplatelet therapy versus observation in low-risk essential thrombocythemia with a CALR mutation

Antiplatelet therapy versus observation in low-risk essential thrombocythemia with a CALR mutation

The role of antiplatelet therapy as primary prophylaxis of thrombosis in low-risk essential thrombocythemia has not been studied in randomized clinical trials. We assessed the benefit/risk of low-dose aspirin in 433 patients with low-risk essential thrombocythemia (271 with a CALR mutation, 162 with...

Full description

Bibliographic Details
Main Authors: Alberto Alvarez-Larrán, Arturo Pereira, Paola Guglielmelli, Juan Carlos Hernández-Boluda, Eduardo Arellano-Rodrigo, Francisca Ferrer-Marín, Alimam Samah, Martin Griesshammer, Ana Kerguelen, Bjorn Andreasson, Carmen Burgaleta, Jiri Schwarz, Valentín García-Gutiérrez, Rosa Ayala, Pere Barba, María Teresa Gómez-Casares, Chiara Paoli, Beatrice Drexler, Sonja Zweegman, Mary F. McMullin, Jan Samuelsson, Claire Harrison, Francisco Cervantes, Alessandro M. Vannucchi, Carlos Besses
Format: Article
Language:English
Published: Ferrata Storti Foundation 2016-08-01
Series:Haematologica
Online Access:https://haematologica.org/article/view/7794

Internet

https://haematologica.org/article/view/7794

Similar Items